Table 3.
Results of logistic regression analyses explaining ANT-adherence in the total sample, clozapine and non-clozapine groups
| Model e | Model f | Model h | Model g | |
|---|---|---|---|---|
| Total sample | OR | OR | OR | OR |
| Age | 1.01 | 1.02 | 1.02 | 1.01 |
| Sex | 2.17 | 1.99 | 1.63 | 2.14 |
| Chlorpromazine equivalent | 1.00 | 1.00 | 1.00 | 1.00* |
| ANT-attitude | 1.04** | 1.04** | 1.03* | 1.03* |
| ANT-insight | 1.00 | 1.00 | 1.00 | 1.01 |
| ANT-adverse effects | 1.02 | 1.02 | 1.01 | 1.01 |
| BPRS_total | 0.97 | |||
| BPRS_positive symptoms | 0.95 | |||
| HONOS_total | 0.96 | |||
| HONOS_behaviour | 1.24 | |||
| HONOS_impairment | 0.94 | |||
| HONOS_symptoms | 0.75 | |||
| HONOS_social | 1.20 | |||
| ADL | 0.73 | 0.73 | 0.77 | 0.74 |
| IADL | 1.19 | 1.22 | 1.2 | 1.25 |
| social functioning | 0.82 | 0.84 | 0.80 | 0.80 |
| Nagelkerke R square | 0.22 | 0.23 | 0.21 | 0.25 |
| p for the model | < 0.001 | < 0.001 | < 0.001 | < 0.001 |
| Non-clozapine group | ||||
| Age | 1.03 | 1.04 | 1.04 | 1.04 |
| Sex | 1.67 | 1.46 | 1.15 | 1.64 |
| Chlorpromazine equivalent | 1.00 | 1.00 | 1.00 | 1.00 |
| ANT-attitude | 1.05** | 1.05** | 1.04* | 1.04* |
| ANT-insight | 1.00 | 1.00 | 0.99 | 1.00 |
| ANT-adverse effects | 1.02 | 1.02 | 1.01 | 1.01 |
| BPRS_total | 0.98 | |||
| BPRS_positive symptoms | 0.98 | |||
| HONOS_total | 1.03 | |||
| HONOS_behaviour | 1.45 | |||
| HONOS_impairment | 1.06 | |||
| HONOS_symptoms | 0.79 | |||
| HONOS_social | 1.34 | |||
| ADL | 0.76 | 0.73 | 0.79 | 0.74 |
| IADL | 1.07 | 1.16 | 1.11 | 1.11 |
| social functioning | 0.85 | 0.85 | 0.79 | 0.84 |
| Nagelkerke R square | 0.29 | 0.30 | 0.26 | 0.33 |
| p for the model | < 0.01 | < 0.001 | < 0.01 | < 0.01 |
| Clozapine group | ||||
| Age | 0.99 | 1.00 | 0.99 | 0.93 |
| Sex | 3.82 | 4.23 | 4.23 | 19.31 |
| Chlorpromazine equivalent | 1.00 | 1.00 | 1.00 | 1.00 |
| ANT-attitude | 1.04 | 1.04 | 1.05 | 1.02 |
| ANT-insight | 1.00 | 1.00 | 0.98 | 1.00 |
| ANT-adverse effects | 1.02 | 1.03 | 1.02 | 1.07 |
| BPRS_total | 0.99 | |||
| BPRS_positive symptoms | 0.96 | |||
| HONOS_total | 0.93 | |||
| HONOS_behaviour | 14.71 | |||
| HONOS_impairment | 0.39 | |||
| HONOS_symptoms | 0.78 | |||
| HONOS_social | 1.11 | |||
| ADL | 2.50 | 2.66 | 1.92 | 2.82 |
| IADL | 1.58 | 1.50 | 1.55 | 2.37* |
| social functioning | 0.78 | 0.84 | 0.79 | 0.71 |
| Nagelkerke R square | 0.24 | 0.25 | 0.30 | 0.38 |
| p for the model | 0.31 | 0.28 | 0.21 | 0.15 |
* p < 0.05 ** p < 0.01 ***p < 0.001
In the presentation of categorical variables: a positive estimate indicates a better adherence for women. A positive estimate indicates a better adherence related to higher score in ANT-scales. High score in ANT -attitude, −insight and -side effect indicates positive attitudes toward medication, better sickness awareness and less experienced side effects. All models adjusted by age, gender, daily antipsychotic dose, ANT-insight, ANT-attitude and ANT-adverse effects